BIOMAT Database Logo BIOMAT Database Logo

Rationale for interleukin-6 blockade in systemic lupus erythematosus. 2004

E Tackey, and P E Lipsky, and G G Illei
Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, USA.

Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biological activities that plays an important role in immune regulation and inflammation. Among other actions, it induces terminal differentiation of B lymphocytes into antibody-forming cells and the differentiation of T cells into effector cells. IL-6 also has multiple potent proinflammatory effects. An association between IL-6 and lupus was demonstrated in murine models of SLE and blocking IL-6 improved lupus in all models tested. Data from several studies suggest that IL-6 plays a critical role in the B cell hyperactivity and immunopathology of human SLE, and may have a direct role in mediating tissue damage. Based on these data, we propose that blocking the effect of IL-6 in humans may improve lupus by interacting with the autoinflammatory process both systemically and locally.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon
D019947 Receptors, Interleukin-6 Cell surface receptors that are specific for INTERLEUKIN-6. They are present on T-LYMPHOCYTES, mitogen-activated B-LYMPHOCYTES, and peripheral MONOCYTES. The receptors are heterodimers of the INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT and the CYTOKINE RECEPTOR GP130. IL-6 Receptors,Interleukin-6 Receptor,Interleukin-6 Receptors,Receptors, IL-6,IL-6 Receptor,IL6 Receptor,IL6 Receptors,Interleukin 6 Receptor,IL 6 Receptor,IL 6 Receptors,Interleukin 6 Receptors,Receptor, IL-6,Receptor, IL6,Receptor, Interleukin 6,Receptor, Interleukin-6,Receptors, IL 6,Receptors, IL6,Receptors, Interleukin 6

Related Publications

E Tackey, and P E Lipsky, and G G Illei
Anti-interleukin-6 and soluble interleukin-6 receptor in systemic lupus erythematosus.
June 1994, Lupus,
E Tackey, and P E Lipsky, and G G Illei
Serum and urinary interleukin-6 in systemic lupus erythematosus.
December 1996, Lupus,
E Tackey, and P E Lipsky, and G G Illei
Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus.
April 2016, Experimental dermatology,
E Tackey, and P E Lipsky, and G G Illei
Interleukin-6 promotes systemic lupus erythematosus progression with Treg suppression approach in a murine systemic lupus erythematosus model.
November 2014, Clinical rheumatology,
E Tackey, and P E Lipsky, and G G Illei
The rationale for BAFF inhibition in systemic lupus erythematosus.
August 2012, Current rheumatology reports,
E Tackey, and P E Lipsky, and G G Illei
The interleukin-6-hepcidin-hemoglobin circuit in systemic lupus erythematosus flares.
February 2017, Lupus,
E Tackey, and P E Lipsky, and G G Illei
Interleukin-6 gene polymorphism in Iranian patients with systemic lupus erythematosus.
February 2011, Clinical rheumatology,
E Tackey, and P E Lipsky, and G G Illei
Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus.
September 1997, European cytokine network,
E Tackey, and P E Lipsky, and G G Illei
Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia.
June 2005, Annals of the rheumatic diseases,
E Tackey, and P E Lipsky, and G G Illei
Clinical analysis of cerebrospinal fluid interleukin-6 in neuropsychiatric systemic lupus erythematosus.
February 2010, Fukuoka igaku zasshi = Hukuoka acta medica,
Copied contents to your clipboard!